The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Other Relationship - Support for third-party writing assistance for this abstract, furnished by Kalina Boytcheva, MSc, of Nucleus Global, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2– locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant (adj) endocrine therapy (ET).
 
Kevin Kalinsky
Employment - EQRx (I); GRAIL (I)
Stock and Other Ownership Interests - EQRx (I); GRAIL (I)
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Cullinan Oncology; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; immunomedics; Lilly; Menarini Silicon Biosystems; Merck; mersana; Myovant Sciences; Novartis; Oncosec; Prelude Therapeutics; Puma Biotechnology; RayzeBio; RayzeBio; Seagen; Takeda
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
Other Relationship - Genentech; Immunomedics
 
Rinath Jeselsohn
Consulting or Advisory Role - AstraZeneca; Carrick Therapeutics; Lilly; Novartis; Pfizer
Research Funding - Lilly; Pfizer
 
Meritxell Bellet
Consulting or Advisory Role - Lilly; Novartis; Pfizer
Speakers' Bureau - Lilly; Novartis; Pfizer
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche
 
Gonzalo Gomez-Abuin
Consulting or Advisory Role - AstraZeneca; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; MSD Oncology; Novartis
Research Funding - AstraZeneca; BMS GmbH & Co. KG; Janssen Oncology; Lilly; MSD Oncology; Novartis; Roche
Travel, Accommodations, Expenses - AstraZeneca; Gador; GlaxoSmithKline; Novartis; Raffo
 
Kyung Hae Jung
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bixink; Celgene; Daiichi Sankyo/Astra Zeneca; Eisai; Eisai; Everest Medicine; Merck; MSD; Novartis; Novartis; Pfizer; Roche; Takeda
 
Sandrine Lavallé
Other Relationship - Support for third-party writing assistance for this abstract, furnished by Kalina Boytcheva, MSc, of Nucleus Global, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Vanesa López-Valverde
Employment - Roche
Stock and Other Ownership Interests - Roche
Other Relationship - Support for third-party writing assistance for this abstract, furnished by Kalina Boytcheva, MSc, of Nucleus Global, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Yen-Shen Lu
Honoraria - AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; EuroPharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Richard B. Schwab
Employment - Genentech/Roche
Stock and Other Ownership Interests - Biosplice (I)
 
Nick Turner
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb; Eli Lilly & Co.; Merck Sharp & Dohme; Novartis; Pfizer; Repare Therapeutics; F. Hoffmann-La Roche; Taiho Pharmaceutical; Zeno Pharmaceuticals
Research Funding - AstraZeneca (Inst); Bio-Rad (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Inivata (Inst); InVitae (Inst); Natera, Inc. (Inst); Personalis (Inst); Pfizer (Inst); F. Hoffmann-La Roche (Inst) (Inst)
Other Relationship - Support for third-party writing assistance for this abstract, furnished by Kalina Boytcheva, MSc, of Nucleus Global, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland
 
Vanessa Breton
Employment - Roche
Stock and Other Ownership Interests - Roche
Other Relationship - Support for third-party writing assistance for this abstract, furnished by Kalina Boytcheva, MSc, of Nucleus Global, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Alberto Zambelli
No Relationships to Disclose
 
Fabrice Andre
Consulting or Advisory Role - Advisory board (self): Lilly; Advisory board or speaker (compensated to the hospital): AstraZeneca, Daiichi Sankyo, Roche, Lilly, Pfizer, Owkin, Novartis, Guardant Health, N-Power Medicine, Servier, Gilead, Boston Pharmaceutics (Inst)
Research Funding - AstraZeneca, Daiichi Sankyo, Roche, Lilly, Pfizer, Owkin, Novartis, Guardant Health (Inst)
Other Relationship - Support for third-party writing assistance for this abstract, furnished by Kalina Boytcheva, MSc, of Nucleus Global, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.